
Loading, please wait...

Loading, please wait...

Amyotrophic lateral sclerosis presents immense clinical and biological heterogeneity. For decades, clinicians regarded classical motor neuron disorders as distinct clinicopathologic entities. However, contemporary genomic discoveries reveal extensive overlap among various adult-onset neurodegenerative syndromes. Traditional molecular diagnostics frequently evaluate only a narrow panel of classic disease-causing genes. Consequently, standard workflows overlook clinically consequential mutations in overlapping neurology genes. Recent whole-genome sequencing investigations confirm that multi-gene adult neurodegenerative panels expand our diagnostic horizon. Incorporating comprehensive ALS genetic screening into routine clinical practice uncovers unexpected molecular etiologies. Furthermore, this broad genetic testing approach reshapes our diagnostic paradigms and informs emerging targeted therapeutic options.
Historically, clinicians relied on narrow gene panels focused primarily on classic loci such as C9orf72, SOD1, TARDBP, and FUS. However, this restricted approach fails to identify non-canonical disease drivers. In a landmark Italian cohort study, investigators performed short-read whole-genome sequencing on 856 consecutively enrolled patients with amyotrophic lateral sclerosis and primary lateral sclerosis. The clinical team phenotyped each patient rigorously under Gold Coast and consensus primary lateral sclerosis diagnostic criteria to eliminate mimics. The researchers systematically analyzed 453 genes linked to adult-onset neurologic disorders. The screening encompassed single-nucleotide variants, short insertions and deletions, and short tandem repeat expansions. The authors adhered strictly to the American College of Medical Genetics and Genomics guidelines to classify pathogenicity. As a result, the authors identified pathogenic or likely pathogenic variants across an unexpectedly broad biological canvas. Moreover, their workflow confirms that targeted sequencing misses clinically vital mutations. Therefore, widespread ALS genetic screening offers clinicians a far more comprehensive picture of underlying neurodegenerative susceptibility.
The investigation yielded remarkable quantitative insights into motor neuron disease architecture. Specifically, 168 of the 856 participants (19.6 percent) carried pathogenic variants or repeat expansions, mostly autosomal dominant. Pathogenic short tandem repeat expansions represented the largest single contributor, accounting for 11.9 percent of the total cohort. Furthermore, five patients carried both deleterious sequence variants and pathogenic repeat expansions simultaneously. Most strikingly, 41 patients, representing 4.8 percent of the entire cohort, harbored pathogenic mutations in non-classical motor genes. These unexpected variants localized to genes traditionally linked to hereditary ataxias, peripheral neuropathies, distal myopathies, movement disorders, mitochondrial disorders, and hereditary spastic paraplegia. Statistical analyses confirmed significant clinical correlations among variant carriers. For instance, variant carriers exhibited a significantly earlier median age at onset compared to non-carriers. In addition, these patients showed marked enrichment for family histories of amyotrophic lateral sclerosis, frontotemporal dementia, and broader neurodegenerative disorders. Consequently, clinicians must recognize that adult-onset neurologic diseases share substantial genomic territory.
Beyond individual gene variants, the study uncovered systemic convergence across distinct cellular mechanisms. Pathway analyses revealed significant biological enrichment in mitochondrial function, cellular metabolism, and proteostasis pathways at a false discovery rate below 0.05. Therefore, motor neuron vulnerability stems from widespread organellar failure rather than isolated cellular defects. For example, mitochondrial respiratory chain dysfunction impairs axonal transport, leaving long motor tracts susceptible to progressive energetic exhaustion. Similarly, disrupted proteostasis promotes toxic intracellular aggregate accumulation across both upper and lower motor pathways. Notably, many identified genes participate directly in autophagy, vesicle trafficking, and lysosomal clearance. These cellular mechanisms also cause hereditary spastic paraplegia, Charcot-Marie-Tooth disease, and spinocerebellar ataxias. Furthermore, metabolic derangements exacerbate excitotoxic stress in spinal motor neurons. These mechanistic insights challenge the historic dogma that amyotrophic lateral sclerosis operates through isolated pathobiology. Instead, shared molecular networks link motor degeneration to diverse adult-onset neurologic disorders. Thus, therapeutic strategies targeting proteostasis or mitochondrial rescue may benefit diverse patient subsets regardless of their initial clinical phenotype.
The study generated crucial findings regarding clinical presentation and molecular architecture. Intriguingly, pathogenic variants in genes classically associated with upper motor neuron dysfunction did not predict an upper motor neuron-predominant phenotype. For example, patients harboring hereditary spastic paraplegia or ataxia mutations showed an odds ratio of only 1.54 for upper motor neuron predominance, which lacked statistical significance. Similarly, researchers could not establish a reliable statistical association between peripheral neuropathy or myopathy genes and lower motor neuron-predominant presentations. This clinical-genomic dissociation highlights the non-deterministic nature of many adult-onset neurologic variants. Consequently, phenotypic manifestations depend heavily on polygenic risk backgrounds, epigenetic modifications, and environmental exposures. Clinicians cannot reliably predict the precise clinical course based solely on the affected gene. Furthermore, interpreting rare sequence variants in non-classical genes requires extreme diagnostic caution. Without matched healthy control cohorts, some rare variants may act as disease modifiers rather than pure monogenic drivers. Therefore, multidisciplinary teams must interpret these complex genomic results alongside comprehensive electrophysiological, imaging, and longitudinal clinical evaluations.
These discoveries hold profound diagnostic and therapeutic implications for clinical neurologists worldwide, including practitioners across India. Traditionally, physicians restricted genetic testing to individuals with documented familial disease. However, sporadic patients frequently harbor high-penetrance mutations or multi-system neurodegenerative risk alleles. In addition, establishing a precise molecular diagnosis ends traumatic diagnostic odysseys for affected families. More importantly, genetic confirmation enables targeted therapy selection and clinical trial enrollment. For example, gene-targeted antisense oligonucleotides already transform management for patients with superoxide dismutase 1 mutations. Global trials currently evaluate novel agents directed against other specific pathways. Furthermore, early genetic diagnosis facilitates timely family counseling and presymptomatic risk stratification. As next-generation sequencing becomes increasingly accessible in Indian tertiary centers, clinicians must transition from narrow single-gene tests to comprehensive multi-gene panels. Moreover, clinicians must pair genomic testing with genetic counseling to address ethical considerations and psychological burdens. Ultimately, systematic screening of adult-onset neurologic disease genes will accelerate precision neurotherapeutics and optimize comprehensive patient care.
Broad panels detect pathogenic variants in overlapping neuromuscular conditions that routine tests miss entirely. In addition, extensive screening identifies atypical presentations across ataxias, neuropathies, and spastic paraplegias. Consequently, clinicians achieve higher diagnostic yields, avoid protracted diagnostic odysseys, and match eligible individuals with emerging targeted precision therapies much earlier in their disease trajectory.
Patients who manifest symptoms at an earlier age carry a substantially higher burden of pathogenic variants. Furthermore, these individuals often demonstrate familial clustering of motor neuron disease or other neurodegenerative conditions. Therefore, younger patients presenting with motor neuron signs warrant urgent, comprehensive genomic sequencing, even when clear classical family histories appear initially absent during intake.
Surprisingly, genomic data show that variants in upper motor neuron disease genes do not reliably predict an isolated upper motor neuron phenotype. Many patients with hereditary spastic paraplegia variants develop classical lower motor signs over time. Thus, clinicians should interpret genomic findings as broad risk drivers rather than strict determinants of selective corticospinal tract degeneration.
Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute professional medical advice, diagnosis, or treatment. Healthcare providers should make individualized clinical decisions based on each patient's medical history. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Whole-genome sequencing of 856 ALS and PLS patients reveals pathogenic variants across 453 adult-onset neurologic disease genes. Learn how broader multigene panels improve diagnostic accuracy, identify shared cellular pathways, and advance precision neurology in clinical practice.
Today

A prospective machine learning study demonstrates that an interpretable XGBoost model using 30 photoplethysmography features accurately estimates continuous blood pressure in intensive care units, achieving Grade A British Hypertension Society standards and reducing reliance on invasive arterial catheters.
Today

A qualitative study on the Dutch HPV vaccination catch-up campaign reveals that young adult hesitancy stems from information gaps and accessibility barriers rather than rampant misinformation. Clinicians can leverage these social listening insights to improve vaccine communication and address patient concerns.
Today

A multicenter longitudinal study of the CHARLS and HRS cohorts demonstrates that elevated cumulative pulse pressure and high-stable trajectories significantly increase incident sarcopenia risk in older adults, particularly in those with heart disease, linking arterial stiffness directly to progressive muscle loss.
Today

A 491-patient cohort study in Sudan reveals critical insights into war trauma reconstructive surgery, analyzing injury patterns, soft-tissue procedures, and a 25.5% complication rate in resource-limited conflict zones.
Today

A secondary analysis of the Living Healthier with Diabetes trial reveals that positive baseline technology attitudes significantly improve engagement with digital diabetes self-management apps, leading to enhanced self-care behaviors and better long-term glycemic control in adults with type 2 diabetes.
Today